Madrigal Pharmaceuticals Executive and Leadership Team

Bill Sibold, the Chief Executive Officer at Madrigal Pharmaceuticals, directs the overarching corporate strategy and long-term vision for the organization. Sibold manages the transition of therapeutic candidates from clinical trials to commercialization, specifically focusing on the development of MGL-3196 for liver-directed treatments. By aligning internal research priorities with external market demands, the Chief Executive Officer ensures the company maintains a competitive edge in the biopharmaceutical sector. Bill Sibold oversees the allocation of capital toward high-impact cardiovascular and metabolic research programs. This leadership role involves constant collaboration with the Board to refine operational goals and secure the necessary resources for Phase II clinical trials. Through rigorous oversight of organizational performance, the Chief Executive Officer drives sustainable growth and maintains the company's reputation as a leader in thyroid hormone receptor agonist research across North American and international markets.

Ronald Filippo, the Executive Vice President & Chief Information Officer at Madrigal Pharmaceuticals, architects the digital infrastructure supporting clinical data management and research operations. Filippo secures the integrity of sensitive patient data generated during Phase II trials for non-alcoholic steatohepatitis. By implementing advanced analytics platforms, the Executive Vice President & Chief Information Officer optimizes the processing of complex metabolic disease datasets. Ronald Filippo manages the integration of secure cloud systems that facilitate seamless communication between global research teams and clinical sites. This leadership role involves mitigating cybersecurity risks while ensuring high availability of critical research tools. Through the deployment of scalable information technology solutions, the Executive Vice President & Chief Information Officer supports the rapid advancement of the company's lead candidate, MGL-3196, ensuring that data-driven insights inform every stage of the drug development lifecycle across the entire enterprise.

Clint Wallace, the Executive Vice President & Chief Human Resources Officer at Madrigal Pharmaceuticals, directs the talent acquisition and organizational development strategies necessary to support clinical-stage biopharmaceutical operations. Wallace cultivates a high-performance culture focused on the specialized expertise required for cardiovascular and liver disease research. By designing comprehensive compensation and retention programs, the Executive Vice President & Chief Human Resources Officer attracts top-tier scientific and clinical talent to the organization. Clint Wallace oversees the alignment of workforce capabilities with the evolving needs of the MGL-3196 development program. This leadership role involves fostering cross-functional collaboration between research, clinical, and commercial teams to ensure operational efficiency. Through the implementation of robust professional development initiatives, the Executive Vice President & Chief Human Resources Officer strengthens the internal human capital required to navigate complex regulatory environments and drive the company's mission forward in the competitive pharmaceutical landscape.

Shannon Kelley, the Executive Vice President & Chief Legal Officer at Madrigal Pharmaceuticals, architects the legal framework governing intellectual property, clinical trial compliance, and corporate governance. Kelley manages the complex regulatory landscape surrounding the development of thyroid hormone receptor agonists. By providing strategic counsel on patent protection for MGL-3196, the Executive Vice President & Chief Legal Officer secures the company's proprietary assets against market competition. Shannon Kelley oversees all contractual obligations and partnership agreements that facilitate the advancement of metabolic disease research. This leadership role involves mitigating legal risks associated with Phase II clinical trials and ensuring adherence to international pharmaceutical standards. Through proactive management of litigation and regulatory filings, the Executive Vice President & Chief Legal Officer protects the company's interests while enabling the efficient execution of clinical development programs across diverse geographic markets and regulatory jurisdictions.

David Soergel, the Executive Vice President & Chief Medical Officer at Madrigal Pharmaceuticals, directs the clinical development strategy for the company's pipeline of cardiovascular and liver disease therapies. Soergel oversees the design and execution of Phase II clinical trials for MGL-3196, ensuring that all research protocols meet rigorous scientific and safety standards. By analyzing clinical data, the Executive Vice President & Chief Medical Officer determines the efficacy of thyroid hormone receptor agonists in treating non-alcoholic steatohepatitis and familial hypercholesterolemia. David Soergel manages interactions with regulatory bodies to facilitate the approval process for new therapeutic candidates. This leadership role involves coordinating with medical experts to interpret trial results and refine the clinical development roadmap. Through the application of deep medical expertise, the Executive Vice President & Chief Medical Officer drives the scientific progress of the company's lead candidates, ultimately aiming to deliver transformative treatments to patients suffering from chronic metabolic conditions.